Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
CLEO Diagnostics Ltd ( (AU:COV) ) has issued an announcement.
Cleo Diagnostics Limited clarifies its unique position as the only ASX-listed company exclusively focused on ovarian cancer diagnostics, using its novel CXCL10 biomarker technology. The company is progressing U.S. clinical trials, aiming for FDA approval, which could significantly impact its market presence and address a critical gap in ovarian cancer detection, potentially improving patient outcomes and strengthening its industry positioning.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd operates in the medical diagnostics industry, focusing on developing a blood test for the early and accurate detection of ovarian cancer. The company leverages its patented biomarker, CXCL10, which distinguishes between malignant and benign ovarian disease, and holds a worldwide exclusive license to commercialize this technology. Cleo Diagnostics aims to address the urgent unmet need for ovarian cancer diagnostics by advancing their test through clinical trials and aims for FDA approval to enter the patient market.
YTD Price Performance: 23.94%
Average Trading Volume: 77,791
Technical Sentiment Consensus Rating: Sell
Learn more about COV stock on TipRanks’ Stock Analysis page.